Abstract 2534
Background
Radiomic signatures offer the potential to enhance clinical decision-making as on-treatment markers of efficacy to assess which patients (pts) should continue treatment. Using treatment-related radiomic signatures via quantitative, artificial intelligence (AI)-based analysis of computed tomography (CT) images, we evaluated early tumor changes in pts with sqNSCLC treated in 2 treatment groups: nivolumab (group A) or docetaxel (group B).
Methods
Data from pts with sqNSCLC were collected prospectively and analyzed retrospectively across 2 multicenter clinical trials (A, n = 92 CheckMate 017 [NCT01642004], CheckMate 063 [NCT01721759]; B, n = 50 CheckMate 017). For the current study, pts with a measurable lung lesion and baseline and on-treatment assessments (8 weeks) were randomized to training (T) or validation (V) datasets (A: 72T, 20V; B: 32T, 18V;). For each pt, the largest measurable lung tumor was segmented to extract 1,749 radiomic features. Pts were classified as treatment-sensitive or -resistant using median progression-free survival (PFS) calculated from pts included in this study (A, B). Using AI-based methodologies, up to 4 features were selected and combined to develop a signature score (range, 0-1) in the T datasets and applied to each pt in the V datasets to classify sensitivity to treatment.
Results
The radiomics features associated with treatment sensitivity in the T datasets were a decrease in tumor volume (A, B), infiltration of tumor boundaries (A), or tumor spatial heterogeneity (A). The radiomic signatures predicted treatment sensitivity in the V dataset of each study group (AUC [95% CI]: A, 0.77 [0.55-1.00]; B, 0.67 [0.37-0.96]).
Conclusions
AI-based CT imaging detected early changes in radiomic features from baseline to first on-treatment tumor assessment—decrease in tumor volume, tumor heterogeneity, and tumor infiltrativeness along boundaries—that were associated with sensitivity to treatment in pts with sqNSCLC, offering an approach that could guide clinical decision-making to continue or modify systemic therapies.
Clinical trial identification
CheckMate 017 [NCT01642004] July 17, 2012 (first posted date) CheckMate 063 [NCT01721759] November 6, 2012 (first posted date).
Editorial acknowledgement
Legal entity responsible for the study
Bristol-Myers Squibb and Columbia University Medical Center.
Funding
Bristol-Myers Squibb.
Disclosure
M. Fronheiser: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. S. Du: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. W. Hayes: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. D.K. Leung: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. A. Roy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. L.H. Schwartz: Research grant / Funding (self), Member DSMB: Merck; Research grant / Funding (self), Member DSMB: Novartis; Research grant / Funding (self), Consultant endpoint analysis: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
4021 - Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
Presenter: Paolo Nuciforo
Session: Poster Display session 3
Resources:
Abstract
5603 - Development of a comprehensive next-generation targeted sequencing assay for detection of gene-fusions in solid tumors
Presenter: Vinay Mittal
Session: Poster Display session 3
Resources:
Abstract
4952 - Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP)
Presenter: Kang Kook Lee
Session: Poster Display session 3
Resources:
Abstract
4590 - Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
Presenter: Michele Ghidini
Session: Poster Display session 3
Resources:
Abstract
3696 - Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma
Presenter: Filip Janku
Session: Poster Display session 3
Resources:
Abstract
4295 - Identification of the founder BRCA1 mutation c.4117G>T (p.Glu1373*) recurring in Abruzzo and Lazio regions of Central Italy and predisposing to breast/ovarian and BRCA1-related cancers
Presenter: Daniela Di Giacomo
Session: Poster Display session 3
Resources:
Abstract
2214 - Enzalutamide (ENZA) and Apalutamide (APA) In vitro chemical reactivity studies and Activity in a Mouse Drug Allergy Model (MDAM)
Presenter: Mausumee Guha
Session: Poster Display session 3
Resources:
Abstract
5044 - Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients.
Presenter: Bram Agema
Session: Poster Display session 3
Resources:
Abstract
3293 - Cardioprotective and anti-inflammatory effects of Empagliflozin during treatment with Doxorubicin: a cellular and preclinical study
Presenter: Vincenzo Quagliariello
Session: Poster Display session 3
Resources:
Abstract
3324 - Breast Cancer Organoids Model Treatment Response of HER2 Targeted Therapy in HER2-mutant Breast Cancer
Presenter: Xuelu Li
Session: Poster Display session 3
Resources:
Abstract